Sukrut Shah
About
Sukrut Shah is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology.
According to data from OpenAlex, Sukrut Shah has authored 61 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Surgery, 25 papers in Pulmonary and Respiratory Medicine and 23 papers in Oncology. Recurrent topics in Sukrut Shah's work include Gastric Cancer Management and Outcomes (21 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Esophageal Cancer Research and Treatment (17 papers). Sukrut Shah is often cited by papers focused on Gastric Cancer Management and Outcomes (21 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Esophageal Cancer Research and Treatment (17 papers). Sukrut Shah collaborates with scholars based in United States, Japan and South Korea. Sukrut Shah's co-authors include Yale Mitchel, Inna Perevozskaya, Thomas Sudhop, Michael Igel, Diane L. Tribble, Dieter Lütjohann, Klaus von Bergmann, Hayes M. Dansky, Philip J. Barter and Antonio M. Gotto and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.
In The Last Decade
Sukrut Shah
60 papers receiving 3.4k citations
Hit Papers
Peers
Sukrut Shah
Jennifer Sugg United States
Antonio González‐Pérez Spain
Masahiro Tsuda Japan
Amy O. Johnson‐Levonas United States
Guoqing Cao China
Mats Rudling Sweden
Hideki Hidaka Japan
Akihiro Inazu Japan
Atsushi Nohara Japan
Patrick M. Moriarty United States
Citations per year, relative to Sukrut Shah Sukrut Shah (= 1×)
peers
Jennifer Sugg
Countries citing papers authored by Sukrut Shah
Since
Specialization
Citations
This map shows the geographic impact of Sukrut Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sukrut Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sukrut Shah more than expected).
Fields of papers citing papers by Sukrut Shah
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sukrut Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sukrut Shah. The network helps show where Sukrut Shah may publish in the future.
Co-authorship network of co-authors of Sukrut Shah
This figure shows the co-authorship network connecting the top 25 collaborators of Sukrut Shah. A scholar is included among the top collaborators of Sukrut Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sukrut Shah. Sukrut Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721.
2.
Lin, Chin‐Yo, Fernando Rivera, Dora L.�W. Kwong, et al.. (2023). 1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study. Annals of Oncology. 34. S863–S863.
3.
Lee, Keun‐Wook, Eric Van Cutsem, Yung‐Jue Bang, et al.. (2022). Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. Clinical Cancer Research. 28(16). 3489–3498.
4.
Janjigian, Yelena Y., Akihito Kawazoe, Patricio Yañez, et al.. (2021). The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 600(7890). 727–730.
5.
Qu, Tingting, et al.. (2021). 1409P Cost-effectiveness of pembrolizumab plus platinum and fluoropyrimidine-based chemotherapy as first-line treatment of advanced esophageal cancer in the United States. Annals of Oncology. 32. S1059–S1060.
6.
Wyrwicz, Lucjan, Kyung-Woo Lee, Eric Van Cutsem, et al.. (2020). 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062. Annals of Oncology. 31. S907–S908.
7.
Özgüroğlu, Mustafa, Kohei Shitara, Kyung-Woo Lee, et al.. (2020). 1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials. Annals of Oncology. 31. S915–S915.
8.
Kato, Ken, Manan Shah, Peter C. Enzinger, et al.. (2020). LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Annals of Oncology. 31. S1192–S1193.
9.
Tabernero, Josep, Eric Van Cutsem, Yung‐Jue Bang, et al.. (2019). Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Annals of Oncology. 30. iv152–iv153.
10.
Bang, Yung‐Jue, Yoon‐Koo Kang, Daniel V.T. Catenacci, et al.. (2019). Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 22(4). 828–837.
11.
Ballantyne, Christie M., Sukrut Shah, Aditi Sapre, et al.. (2017). A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American Journal of Cardiology. 120(4). 569–576.
12.
Ballantyne, Christie M., Sukrut Shah, Uma Kher, et al.. (2016). Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American Journal of Cardiology. 119(3). 388–396.
13.
Kastelein, John J.P., Joost Besseling, Sukrut Shah, et al.. (2015). Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. 385(9983). 2153–2161.
14.
Gotto, Antonio M., Christopher P. Cannon, Sukrut Shah, et al.. (2011). Abstract 15035: Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. Circulation. 124(10). 3673–81.
15.
Shah, Sukrut, Anne Hermanowski‐Vosatka, Gang Jia, et al.. (2011). Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. Journal of the American Society of Hypertension. 5(3). 166–176.
16.
Gutstein, David E., Rajesh Krishna, Douglas G. Johns, et al.. (2011). Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction. Clinical Pharmacology & Therapeutics. 91(1). 109–122.
17.
Lewin, Andrew, Mark Kipnes, Luigi Meneghini, et al.. (2004). Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics. 26(3). 379–389.
18.
Shah, Sukrut, et al.. (1998). The effects of antisense to Giα2 on opioid agonist potency and Giα2 protein and mRNA abundance in the mouse. Molecular Brain Research. 59(2). 247–255.
19.
Shah, Sukrut, et al.. (1997). Time-Dependent Effects of In Vivo Pertussis Toxin on Morphine Analgesia and G-Proteins in Mice. Pharmacology Biochemistry and Behavior. 56(3). 465–469.
20.
Yoburn, Byron C., et al.. (1994). Opioid antagonist-induced receptor upregulation: Effects of concurrent agonist administration. Brain Research Bulletin. 33(2). 237–240.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jennifer Sugg Breakdown of academic impact, for papers by Antonio González‐Pérez Breakdown of academic impact, for papers by Masahiro Tsuda Breakdown of academic impact, for papers by Amy O. Johnson‐Levonas Breakdown of academic impact, for papers by Guoqing Cao Breakdown of academic impact, for papers by Mats Rudling Breakdown of academic impact, for papers by Hideki Hidaka Breakdown of academic impact, for papers by Akihiro Inazu Breakdown of academic impact, for papers by Atsushi Nohara Breakdown of academic impact, for papers by Patrick M. Moriarty